The Company commented: “We are committed to ensuring continued access to high quality, off-patent medicines for patients in the UK and provide many medicines which offer significant savings to the NHS.
ADVANZ PHARMA Corp. today announced it has successfully completed the Company's global rebranding following shareholder approval of its name change last week.
Concordia International Corp. announced today that its shareholders voted in favour of changing its name to ADVANZ PHARMA Corp.
As described in the Company's management information circular dated May 15, 2018, and previous press releases issued in connection with the Recapitalization Transaction, the terms of the Recapitalization Transaction and the CBCA Plan, including the terms and US$13.69 issue price of the Private Placement, were extensively negotiated among the Company, holders of its secured debt, holders of its unsecured debt, the participants in the Private Placement, and their respective advisors.
The Name Change is subject to approval by Limited Voting Shareholders ("Shareholders") at the Meeting.
The Company intends to rebrand as ADVANZ PHARMA during the fourth quarter of 2018.
International specialty pharmaceutical company focused on becoming a leader in European specialty, off patent medicines, today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. Ms. Cloud's appointment will take effect on November 1, 2018.
Third quarter net income of $1.8 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's recently completed transaction to realign its capital structure (the "Recapitalization Transaction")
Update on the implementation of Concordia's recapitalization transaction.
Update On Concordia's Recently Completed Recapitalization
Concordia International Corp. Announces Second Quarter 2018 Results
Update on Concordia's Recapitalization Transaction
Concordia Completes Recapitalization Transaction